The rise and fall of the COX-2 inhibitors
... in patients with congestive heart failure found lower mortality in patients treated with celecoxib than with rofecoxib and traditional NSAIDs. 52 These results should be interpreted with caution. For example the two studies contradict each other as regards the similar risk of myocardial infarction f ...
... in patients with congestive heart failure found lower mortality in patients treated with celecoxib than with rofecoxib and traditional NSAIDs. 52 These results should be interpreted with caution. For example the two studies contradict each other as regards the similar risk of myocardial infarction f ...
Monday 23rd December: PSA2
... A 45-year-old man is found by his GP to have persistently raised blood pressure over the previous month. His baseline biochemical profile is normal. The GP prescribes candesartan cilexetil 8 mg orally daily. Question Select the most appropriate monitoring option to assess the adverse effects of this ...
... A 45-year-old man is found by his GP to have persistently raised blood pressure over the previous month. His baseline biochemical profile is normal. The GP prescribes candesartan cilexetil 8 mg orally daily. Question Select the most appropriate monitoring option to assess the adverse effects of this ...
Glycopeptides, Oxazolidinones, Streptogramins and
... binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit; this action prevents the formation of a functional 70S initiation complex, an essential step in the bacterial translation process ...
... binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit; this action prevents the formation of a functional 70S initiation complex, an essential step in the bacterial translation process ...
COX-2 inhibitor article for exam (medscape)
... Konstam et al.[6] performed a meta-analysis of 23 placebo- and NSAID-controlled studies with rofecoxib, including 26,000 patients. They concluded that treatment with rofecoxib was associated with an increased risk of a thrombotic cardiovascular event when compared with naproxen, but not when compare ...
... Konstam et al.[6] performed a meta-analysis of 23 placebo- and NSAID-controlled studies with rofecoxib, including 26,000 patients. They concluded that treatment with rofecoxib was associated with an increased risk of a thrombotic cardiovascular event when compared with naproxen, but not when compare ...
Aspirin/Dipyridamole
... Capsule: Dipyridamole extended release 200 mg/Aspirin 25 mg Efficacy: Aggrenox has demonstrated clinical efficacy in the prevention of secondary stroke and TIA in patients who have had a stroke or TIA. The clinical effects of its two antiplatelet agents are additive and significantly better than eit ...
... Capsule: Dipyridamole extended release 200 mg/Aspirin 25 mg Efficacy: Aggrenox has demonstrated clinical efficacy in the prevention of secondary stroke and TIA in patients who have had a stroke or TIA. The clinical effects of its two antiplatelet agents are additive and significantly better than eit ...
Theranostics Polysaccharide Nanosystems for Future Progress in
... synthetic polymers is their low biodegradability. However, some synthetic polymers are known to degrade in vivo, most belonging to polyester family, which includes polyglycolides and polylactides. Even though, they still present poor biocompatibility, loss of mechanical properties during degradation ...
... synthetic polymers is their low biodegradability. However, some synthetic polymers are known to degrade in vivo, most belonging to polyester family, which includes polyglycolides and polylactides. Even though, they still present poor biocompatibility, loss of mechanical properties during degradation ...
Anticoagulants, Thrombolytics Agents and Antiplatelet Drugs
... 1. Schafer AI. Am J Med 1996; 101: 199–209. ...
... 1. Schafer AI. Am J Med 1996; 101: 199–209. ...
azopt - Vision Institute of Canada
... (Brinzolamide 1%) Ophthalmic Suspension in the affected eye(s) two times daily. If the clinical response is not adequate after 4 weeks, the dosage may be increased to 1 drop three times ...
... (Brinzolamide 1%) Ophthalmic Suspension in the affected eye(s) two times daily. If the clinical response is not adequate after 4 weeks, the dosage may be increased to 1 drop three times ...
Algorithms for Diagnosis of Disorders in Hemostasis
... (AT-III), Proteins C & S, Plasminogen, Thrombin Time and Reptilase Time, ...
... (AT-III), Proteins C & S, Plasminogen, Thrombin Time and Reptilase Time, ...
DICLOFENAC-GA PRODUCT INFORMATION DICLOFENAC-GA
... Gastrointestinal effects - All NSAIDS can cause gastrointestinal discomfort and serious, potentially fatal gastrointestinal effects such as ulcers, bleeding and perforation which may increase with dose or duration of use, but can occur at any time without warning. Studies to date have not identified ...
... Gastrointestinal effects - All NSAIDS can cause gastrointestinal discomfort and serious, potentially fatal gastrointestinal effects such as ulcers, bleeding and perforation which may increase with dose or duration of use, but can occur at any time without warning. Studies to date have not identified ...
IMMUNOSUPPRESSION Standard dose regimen has been given in
... Tacrolimus or cyclosporine. Tacrolimus is available as Prograf (twice daily) andAdvagraf (once daily). Prograf is to be prescribed following liver transplantation at a dose of 2mg bd for patients less than 70kg and 3mg bd for over 70kg. Cyclosporine is to be prescribed as Neoral. Dosing The dosage o ...
... Tacrolimus or cyclosporine. Tacrolimus is available as Prograf (twice daily) andAdvagraf (once daily). Prograf is to be prescribed following liver transplantation at a dose of 2mg bd for patients less than 70kg and 3mg bd for over 70kg. Cyclosporine is to be prescribed as Neoral. Dosing The dosage o ...
voltaren - GuildLink
... was 3 to 6 hours. Only 4 to 6 hours after administration, therefore, concentrations of the active substance were already higher in the synovial fluid than they were in the plasma and remained higher for up to 12 hours. These results could possibly explain that the duration of clinical effect is long ...
... was 3 to 6 hours. Only 4 to 6 hours after administration, therefore, concentrations of the active substance were already higher in the synovial fluid than they were in the plasma and remained higher for up to 12 hours. These results could possibly explain that the duration of clinical effect is long ...
Warfarin – INR – Antibiotic Interactions
... increase INR and the effects of warfarin ***S-warfarin is 2-5 times more active than the R-enantiomer Related Information: A challenging aspect of warfarin management has always been keeping patients’ INR within the therapeutic window. Once on a stable dose of warfarin, numerous factors can affect I ...
... increase INR and the effects of warfarin ***S-warfarin is 2-5 times more active than the R-enantiomer Related Information: A challenging aspect of warfarin management has always been keeping patients’ INR within the therapeutic window. Once on a stable dose of warfarin, numerous factors can affect I ...
E3 - Viktor`s Notes for the Neurosurgery Resident
... with ancestry across broad areas of Asia, including South Asian Indians - patients with ancestry from these areas should be screened for the HLA-B*1502 allele before starting treatment with CARBAMAZEPINE (if test positive, carbamazepine should not be started); patients who have been taking CARBAMAZE ...
... with ancestry across broad areas of Asia, including South Asian Indians - patients with ancestry from these areas should be screened for the HLA-B*1502 allele before starting treatment with CARBAMAZEPINE (if test positive, carbamazepine should not be started); patients who have been taking CARBAMAZE ...
Asthma
... NOT a bronchodilator - it should NOT be used to treat acute episodes of asthma. • Reassess therapy if short-acting bronchodilators are needed more often than usual • Monitor patients on a regular basis - the most serious adverse reaction is elevation of liver enzymes. ...
... NOT a bronchodilator - it should NOT be used to treat acute episodes of asthma. • Reassess therapy if short-acting bronchodilators are needed more often than usual • Monitor patients on a regular basis - the most serious adverse reaction is elevation of liver enzymes. ...
Product Monograph
... As with other triptans, eletriptan may cause coronary artery vasospasm. Serious adverse cardiac events, including acute myocardial infarction, life-threatening disturbances of cardiac rhythm, and death have been reported within a few hours following the administration of other 5-HT1 agonists. Consid ...
... As with other triptans, eletriptan may cause coronary artery vasospasm. Serious adverse cardiac events, including acute myocardial infarction, life-threatening disturbances of cardiac rhythm, and death have been reported within a few hours following the administration of other 5-HT1 agonists. Consid ...
voltaren - GuildLink
... In a study in 16 patients with rheumatoid arthritis and knee joint effusions it was found that diclofenac enters the synovial fluid, where maximum concentrations were measured 2 to 4 hours after oral administration. The apparent half-life for elimination from the synovial fluid was 3 to 6 hours. Onl ...
... In a study in 16 patients with rheumatoid arthritis and knee joint effusions it was found that diclofenac enters the synovial fluid, where maximum concentrations were measured 2 to 4 hours after oral administration. The apparent half-life for elimination from the synovial fluid was 3 to 6 hours. Onl ...
Chapter 34 Antihypertension Drugs
... The physician must establish with certainty that hypertension is persistent and requires treatment and must exclude secondary causes of hypertension that might be treated by definitive surgical procedures. ...
... The physician must establish with certainty that hypertension is persistent and requires treatment and must exclude secondary causes of hypertension that might be treated by definitive surgical procedures. ...
May 2011 Issue
... successful PCI with drug-eluting stent implantation in 2800 patients.5 The 2214 nonresponders with high residual platelet reactivity (defined as platelet reactivity units >230) were randomly assigned to continue to receive clopidogrel 75 mg/day (standard therapy) or an additional clopidogrel 600-mg ...
... successful PCI with drug-eluting stent implantation in 2800 patients.5 The 2214 nonresponders with high residual platelet reactivity (defined as platelet reactivity units >230) were randomly assigned to continue to receive clopidogrel 75 mg/day (standard therapy) or an additional clopidogrel 600-mg ...
I. Angina Pectoris
... Tinzaparin (Innohep) and Danaparoid (Orgaran) - low molecular weight heparins; more bioavailable, longer acting and perhaps less likely to cause hemorrhage than standard heparin. ...
... Tinzaparin (Innohep) and Danaparoid (Orgaran) - low molecular weight heparins; more bioavailable, longer acting and perhaps less likely to cause hemorrhage than standard heparin. ...
FIXED DOSE COMBINATION PRODUCTSOF ANTI-HYPERTENSIVE’SAND ANTI-DIABETIC’S -
... two or more active ingredients in a fixed ratio of doses in the same formulation [1, 2]. FDCs are formulated to have a similar bioequivalence of the two agents as separate tablets and therefore have similar pharmacokinetic and pharmacodynamic properties as the separate tablets [3]. FDCs proposed uti ...
... two or more active ingredients in a fixed ratio of doses in the same formulation [1, 2]. FDCs are formulated to have a similar bioequivalence of the two agents as separate tablets and therefore have similar pharmacokinetic and pharmacodynamic properties as the separate tablets [3]. FDCs proposed uti ...
51th ICAAC Chicago, IL September 17
... Four reports at this meeting spelled out early findings on BI 224436, an HIV integrase inhibitor with a mechanism different from that of the "tegravir" strand-transfer integrase inhibitors. This novel agent, being developed by Boehringer Ingelheim, binds to a highly conserved allosteric pocket of th ...
... Four reports at this meeting spelled out early findings on BI 224436, an HIV integrase inhibitor with a mechanism different from that of the "tegravir" strand-transfer integrase inhibitors. This novel agent, being developed by Boehringer Ingelheim, binds to a highly conserved allosteric pocket of th ...
Direct Oral Anticoagulants (DOACs) for DVT and PE in adults
... recurrent VTE in adults. Rivaroxaban is also licensed for prevention of stroke and systemic embolism in adult patients with non valvular AF, and prophylaxis of venous thromboembolism in adults after total hip or total knee replacement surgery. Long term safety data is limited to the duration of trea ...
... recurrent VTE in adults. Rivaroxaban is also licensed for prevention of stroke and systemic embolism in adult patients with non valvular AF, and prophylaxis of venous thromboembolism in adults after total hip or total knee replacement surgery. Long term safety data is limited to the duration of trea ...
Effects of Advanced Liver Disease on drug PK
... Both, however, recovered more than 2 months after transplantation, indicating that either mature hepatocytes or a subpopulation of adult stem cells are capable of full recovery in severe cirrhosis. Transplantation studies indicate that the state of the host microenvironment is critical to the regene ...
... Both, however, recovered more than 2 months after transplantation, indicating that either mature hepatocytes or a subpopulation of adult stem cells are capable of full recovery in severe cirrhosis. Transplantation studies indicate that the state of the host microenvironment is critical to the regene ...
Antifungal Agents - University of Minnesota
... Candida species (? more potent vs fluconazole against C krusei) and Aspergillus sp. resistant to Ampho B or itraconazole • BID dosing via IV or PO routes • Side effects- retinal visual disturbances (self-limited) ...
... Candida species (? more potent vs fluconazole against C krusei) and Aspergillus sp. resistant to Ampho B or itraconazole • BID dosing via IV or PO routes • Side effects- retinal visual disturbances (self-limited) ...
Discovery and development of direct thrombin inhibitors
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a more safer anticoagulant.